Molecular cancer therapeutics
Preclinical development of MGC028, an ADAM9-targeted, glycan-linked, exatecan-based antibody-drug conjugate for the treatment of solid cancers.
Juniper A Scribner, Jennifer G Brown, Thomas Son, Linda Jin, Carroll McKenzie, Viktoriya Nam, Curtis Bush, Dienis Quinonez, Delta Ford, James Tamura, Sergey Gorlatov, Antwanette Summers, Monirath Hav, Hua Li, Neel K Sharma
Published: 202510.1158/1535-7163.MCT-25-0461
Abstract
ADAM9, a member of the ADAM family of multifunctional type 1 transmembrane proteins, is an attractive target for cancer treatment owing to its overexpression in multiple tumors and its role in tumorigenesis and cancer progression. A maytansine-based…
Preview only. Read the full abstract at the source